An official website of the United States government
Home
Name
Abecma
Alternate Names
Idecabtagene vicleucel
Anti-BCMA CAR T Cells BB2121
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
CAR-T
NSC Number
None
Primary Site
None
Histology
Multiple myeloma
Remarks
April 5, 2024 FDA approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial.
March 26, 2021: FDA approved idecabtagene vicleucel (Abecma) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma.
March 26, 2021: FDA approved idecabtagene vicleucel (Abecma) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma.
Coding
This drug should be coded
